AT&T and 2 Dow 30 Stocks Investors are Watching
EI DuPont de Nemours & Co. (NYSE:DD) subsidiary DuPont Nutrition & Health, which supplies rapid molecular diagnostic systems and Seegene, which develops multiplex molecular technologies and diagnostic tests, are partnering to jointly develop new, highly multiplexed assays for use in the detection of foodborne pathogens.
Johnson & Johnson’s (NYSE:JNJ) Janssen division reports that its Xarelto drug has been rejected for approval by the FDA’s Cardiovascular and Renal Drugs Advisory Committee. The med is an oral anticoagulant, designed to reduce the risk of secondary cardiovascular events in patients with Acute Coronary Syndrome in combination with standard antiplatelet therapy. However, Xarelto has been approved in the United States for the reduction of blood clots in the legs and lungs of patients who have just had knee or hip replacement surgery, and also to decrease the risk of both hemorrhagic and thrombotic strokes, plus other blood clots in people with atrial fibrillation not caused by a heart valve problem.
AT&T, Inc. (NYSE:T): NVIDIA’s (NASDAQ:NVDA) SVP of Mobile Communications says that the firm’s NVIDIA Icera 410 LTE multimode data modem chipset for tablets and clamshell devices has been tested and validated for operation on the AT&T 4G LTE network, adding that “Validation with AT&T is an achievement that paves the way for NVIDIA Icera-powered LTE devices on the AT&T network through this year and next.”.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
Investing Insights: Is Siri An Embarrassment to the Jobs Legacy?